Pricing Log in Create free account
Friday 6 November 2026 Export MANE’s income statement to Excel — free account

Veradermics Incorporated

MANE Healthcare Biotechnology

138.19 9.59 +7.46%
Market cap
$5.4B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Veradermics Incorporated (MANE) SEC filings, changes and red flags

Red flags

No red flags have been raised by Veradermics Incorporated’s filings on file.

Filings

Form Period Filed What it reports Flags
8-K Oct 19, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026 P1I2: 16 added · 2 removed · 15 modified
P2I1A: no comparison — low extraction confidence
8-K Aug 11, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jul 15, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 12, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 1, 2026 1.01 Entry into a material definitive agreement; 3.02 Unregistered sales of equity securities; 9.01 Financial statements and exhibits
8-K Apr 27, 2026 2.02 Results of operations and financial condition
8-K Apr 27, 2026 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: no comparison — no earlier filing on file
1A: no comparison — no earlier filing on file
7: no comparison — no earlier filing on file
8-K Mar 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 5, 2026 5.03 Amendments to the articles or bylaws; change in fiscal year; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.